Kanaly Trust’s Regeneron Pharmaceuticals REGN Stock Holding History

Kanaly Trust’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$11K	Sell	29 -5	-15%	-$1.9K	﹤0.01%	536
2016 Q3	$14K	Buy	34 +10	+42%	+$4.01K	﹤0.01%	478
2016 Q2	$8K	Hold	24	–	–	﹤0.01%	577
2016 Q1	$9K	Sell	24 -2	-8%	-$824	﹤0.01%	564
2015 Q4	$14K	Sell	26 -3	-10%	-$1.63K	﹤0.01%	502
2015 Q3	$13K	Buy	29 +5	+21%	+$2.69K	﹤0.01%	514
2015 Q2	$12K	Buy	24 +12	+100%	+$5.86K	﹤0.01%	530
2015 Q1	$5K	Buy	12 +2	+20%	+$848	﹤0.01%	520
2014 Q4	$4K	Buy	10 +2	+25%	+$787	﹤0.01%	549
2014 Q3	$3K	Hold	8	–	–	﹤0.01%	629
2014 Q2	$2K	Hold	8	–	–	﹤0.01%	651
2014 Q1	$2K	Buy	+8	New	+$2.46K	﹤0.01%	639

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Kanaly Trust's REGN Position: Q4 2016 in Review

Kanaly Trust reduced its Regeneron Pharmaceuticals (REGN) stake by 15% in Q4 2016, selling an estimated $1.9K and leaving 29 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #536.

Kanaly Trust first reported a position in REGN in Q1 2014 and has held it in 12 quarters since. The position peaked at $14K in Q3 2016. 576 funds tracked by Wall St. Rank hold REGN as of Q4 2016.

Kanaly Trust held 29 shares of Regeneron Pharmaceuticals worth $11K as of Q4 2016.
Kanaly Trust sold 5 Regeneron Pharmaceuticals shares in Q4 2016, an estimated $1.9K.
Regeneron Pharmaceuticals made up ﹤0.01% of Kanaly Trust's portfolio in Q4 2016, its #536 holding.
Kanaly Trust first reported a position in Regeneron Pharmaceuticals in Q1 2014 and has held it in 12 quarters since.
Kanaly Trust's Regeneron Pharmaceuticals position peaked at $14K in Q3 2016.
576 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2016.

Based on Kanaly Trust's 13F filing for Q4 2016, filed 23 Jan 2017.